CHILDHOOD CANCER ACADEMIC-INDUSTRY COLLABORATIVE PLATFORM TRIALS (C3PT)

Panelist Biographies

Toolkit Launch Webinar

09/2026

MRCT CENTER
THE MULTI-REGIONAL CLINICAL TRIALS CENTER OF BRIGHAM AND WOMEN'S HOSPITAL AND HARVARD

ITCC
INNOVATIVE THERAPIES FOR CHILDREN AND ADOLESCENTS WITH CANCER

Blood Cancer United

CHILDREN'S ONCOLOGY GROUP

PANELIST BIOGRAPHIES

Amos Burke, MB ChB, PhD, MA is Professor of Paediatric Oncology at the University of Birmingham and an Honorary Consultant Paediatric Oncologist at Birmingham, Women and Children's Hospital. He is Head of Department and Director of the University of Birmingham Cancer Research UK Clinical Trials Unit (CRCTU) that delivers a trial portfolio over a wide range of cancers occurring in children, young people and adults. His research is focussed on childhood non-Hodgkin lymphoma and he is Chief Investigator for the innovative platform trial Glo-BNHL for children with relapsed and refractory mature B-cell Non-Hodgkin Lymphoma.

Martha Donoghue, MD is a pediatric oncologist and the Associate Director for Pediatric Oncology and Rare Cancers in the FDA Oncology Center of Excellence. She also serves as the Acting Associate Director for Pediatric Oncology in the FDA Office of Oncologic Diseases. In these roles, she oversees implementation of regulations designed to promote timely investigation of drugs and biological products for pediatric patients with cancer, supports work relating to pediatric oncology and rare cancer drug development across FDA, and works with stakeholders to address challenges and foster development of drugs to treat pediatric and other rare cancers. Prior to joining FDA in 2009, Dr. Donoghue completed a fellowship in Pediatric Hematology and Oncology at the Children's National Medical Center after working for several years as a general pediatrician in private practice. She received her medical degree from Emory University and completed a residency in general pediatrics at the Georgetown University Medical Center.

Elizabeth Fox, MD leads regulatory and clinical trial operations as well clinical research prioritization and strategy at St Jude Children's Research Hospital. Nationally, she is the chair of Developmental Therapeutics for the Children's Oncology Group and the Pediatric Early Phase Clinical Trials Network. Dr. Fox is a pediatric oncologist with expertise in quantitative clinical and pre-clinical pharmacology, pediatric clinical oncology, and clinical research and trial design including response and toxicity biomarker endpoint development. She applies an integrative approach to clinical drug development utilizing animal models, pre-clinical and clinical pharmacology to evaluate new therapies and novel trial designs and improve outcome for children with catastrophic diseases.

Dominik Karres, MD holds a medical degree in paediatric drug development. He held a training post in paediatric haematology/oncology in Germany, followed by posts in paediatric oncology drug development in the UK. With over 10 years in drug regulation and different scientific roles at the UK's MHRA, he is now Senior Scientific Officer in the Paediatric Medicines Office at EMA.

He oversees scientific evaluations of anti-cancer drug development plans (PIPs) and supports the agency's efforts to foster paediatric global drug development in various roles and responsibilities in line with EU policy initiatives. In that capacity he is, for example, the EMAs nominee to the scientific committee of ACCELERATE and leads the European ICH E11A implementation activities.

Additionally, he has been appointed HTA/payer engagement specialist, supporting the regulatory/HTA interface under the new HTA Regulation.

Pamela Kearns, OBE, PhD, FRCPCH is Emeritus Professor of Clinical Paediatric Oncology at the University of Birmingham, where she was Director of the Cancer Research UK Clinical Trials Unit 2011-2023 and Director of the Institute of Cancer and Genomic Sciences 2021–2024.

She is President of ITCC and a Founding Board member of ACCELERATE. She was President of SIOPE 2019–2021 and on the SIOPE Board until December 2024.

She chairs UK's IMPACCT (Initiative for Multi-stakeholder Partnership to Accelerate Children's Cancer Trials). And chairs the Research Assessment Panel for Great Ormond Street Hospital. She is a member of UK's National Institute for Health Research Invention for Innovation Funding Committee as well as several academic advisory boards. She is a Deputy Chair of the Board of Trustees for Cancer Research UK and Chair of the Board of Trustees for A Child of Mine, a charity dedicated to supporting bereaved parents. She was awarded an OBE in the 2026 King's Birthday Honours List for services to cancer research.

George Kirk, PhD has been at AstraZeneca for 30 years and has spent the last 16 years supporting Oncology projects and is currently VP Global Franchise Head (GFH) overseeing a number of late stage projects, including Puxi-Sam (B7H4 ADC); Torvu-Sam (FRα ADC); Sone-Ve (CLDN18.2 ADC); Savolitinib (MET inhibitor); Monalizumab (NK2GA inhibitor) and Oleclumab (CD73 inhibitor), focusing on a range of tumour types, including Endometrial Cancer, Ovarian Cancer, NSCLC and Gastric Cancer. George also leads the Paediatric Oncology Development Team (PODT) which develops and delivers paediatric strategies for programs across AstraZeneca's oncology portfolio.
The PODT is a new team in AstraZeneca Oncology formed

to help prioritise activities to develop better medicines for paediatric patients with cancer with initial focus on paediatric brain tumours and sarcomas. George is also responsible for the leadership of the Oncology Sub-Cutaneous Strategy team.

Previously George was the Global Product Leader (GPL) for Koselugo (selumetinib), a program he worked on since it entered late stage development in 2012. George was instrumental in driving the Koselugo program forward and played a pivotal role in achieving approval from US in 2020 and the EU in 2021 for the treatment of children with NF1-PN. In this role George successfully collaborated with the team at the NIH, NTAP, CTEP/NCI and the CTF to support the Koselugo development program.

Prior to the above George spent his first 14 years in AstraZeneca as a Project Manager and Team Manager in Pharmaceutical Development. During his time in these roles he worked on a variety of Oncology, Infection and Respiratory and Inflammation projects in both Early and Late Phase Development. George's background/training is Chemistry, having a PhD in Organic Chemistry from the University of Strathclyde in Glasgow and he also undertook an oncology preceptorship program at St James' hospital in Leeds in 2014.

Amanda Monteiro, LMSW In 2018, Amanda's first born daughter, Edie, died from acute myeloid leukemia at just 20 months old — an experience that propelled her into palliative care and ignited a lifelong commitment to advocacy for children with cancer and the families who love them.

Amanda is a Licensed Clinical Social Worker specializing in palliative and critical care, working alongside patients and families navigating serious illness, advance care planning, and loss. She advocates for children with cancer and their families, collaborating with the Multi-Regional Clinical Trial Center, Blood Cancer United, and other organizations dedicated to accelerating treatments for children. Amanda has most recently joined as an advocate on the Trial Steering Committee for GLO-BNHL and Blood Cancer United's Research Committee for the Real World Evidence Initiative. She brings additional expertise in healthcare strategy, quality improvement, and program design.

Kerri Nottage, MD, MPH is a Pediatric Hematologist/Oncologist and is currently serving as Senior Director, Pediatric Drug Development within the Child Health Innovation and Leadership Department at Johnson & Johnson. She is currently the Clinical Leader of the Pediatric Oncology Strategy Team and responsible for pediatric strategy for all compounds within the Oncology Therapeutic Area. Prior to this role, Kerri spent 9 years in Hematology Late Development at Johnson & Johnson serving as the Clinical Leader for multiple programs in the myeloid portfolio as well as Tecvayli™, Talvey™, Imbruvica®, and Darzalex®. In addition to these clinical activities, Kerri has been Chair of the Pediatric Working Group for MPAACT—an initiative to establish MRD as an acceptable surrogate endpoint in AML clinical trials to expedite bringing novel therapies to market. Kerri earned her Medical Degree from Brown University and a Master's in Public Heath from the University of Memphis. She completed her residency at Brown University in both Internal Medicine and Pediatrics and subsequently trained in Pediatric Hematology/Oncology at St. Jude Children's Research Hospital in Memphis, TN. She was an academic faculty member in the Department of Hematology at St. Jude prior to coming to Johnson & Johnson.

Continues on the next page

Nicole Scobie is the Chair of ACCELERATE and long-serving member of its Scientific Steering Committee, and is a founding member and president-emeritus of Zoé4life, a Swiss non-profit supporting children with cancer, their families, and research. As a parent of a childhood cancer survivor, she advocates for better treatment access and the development of improved therapies. With extensive experience in incorporating patient perspectives into research strategies and clinical trial design, Nicole is a founding member of the ITCC and SIOPEN Advocate Committees. She serves on the board of CAC2, an international childhood cancer umbrella organization, and is a member of CCI-Europe's R&I committee. She is part of Strategic Advisory Boards for LifeArc as well as ITCC P4, and the Canadian ACCESS External Advisory Board. She is also in the TMG for the GLO-BNHL platform trial.

Learn more about the C3PT Toolkit Launch Webinar here:

https://mrctcenter.org/tribe-events/childhood-cancer-academic-industry-collaborative-platform-trials-c3pt-toolkit-launch-webinar/